Open Access

ARTICLE

Mesenchymal stem cells transplantation attenuates experimentally induced brain injury after neonatal hypoxia by different two routes of administrations

by Nesrine EBRAHIM, Eman EHSAN, Eman Abd EL GHANY, Dina SABRY, Ashraf SHAMAA

1 Histology and Cell Biology Department, Faculty of Medicine, Benha University, Benha, Egypt
2 Pediatrics Department, Faculty of Medicine, Cairo University, Giza, Egypt
3 Medical Biochemistry and molecular biology Department, Faculty of Medicine, Cairo University, Giza, Egypt
4 Surgical and Radiology Department, Faculty of Veterinary Medicine, Cairo University, Giza, Egyp

* Address correspondence to: Nesrine Ebrahim,

BIOCELL 2019, 43(1), 21-28. https://doi.org/10.32604/biocell.2019.06111

Abstract

The neonatal hypoxic–ischemic encephalopathy (HIE) is an important cause of neurological morbidity and mortality in neonates. Cell therapy is considered a promising method for treating severe neurological disorders such as this one. Stem cells have the capacity for self-renewal and differentiation into certain cell lineages. The present study was aimed to find out the most beneficial route of bone marrow-derived mesenchymal stem cells (BMSCs) administration for the attenuation of experimentally induced HIE in neonatal rats. Sixty neonatal rats were divided randomly into four groups. Group 1: control group. Group 2: rats were exposed to bilateral ligation of cephalic arteries. Group 3: rats were exposed to bilateral ligation of cephalic arteries and then underwent intravenous (IV) BMSC injection. Group 4: rats were exposed to bilateral ligation of cephalic arteries and then underwent intracerebroventricular (ICV) BMSC injection. The animals were evaluated by (a) neurobehavioral tests; (b) histopathology, i.e., histological and immunohistochemical studies; and (3) gene expression studies. The BMSC treated groups (3 and 4) showed improvement in neurobehavioral tests, histopathological studies, and gene expression, as compared to non-injected lesioned rats (Group 2) with better improvement in Group 4 (ICV injections) than in Group 3 (IV injections).

---

Keywords

---

Citations